EA201070625A1 - Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества - Google Patents

Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества

Info

Publication number
EA201070625A1
EA201070625A1 EA201070625A EA201070625A EA201070625A1 EA 201070625 A1 EA201070625 A1 EA 201070625A1 EA 201070625 A EA201070625 A EA 201070625A EA 201070625 A EA201070625 A EA 201070625A EA 201070625 A1 EA201070625 A1 EA 201070625A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sdl
water
delivery system
active substance
amfila
Prior art date
Application number
EA201070625A
Other languages
English (en)
Other versions
EA018636B1 (ru
Inventor
Джулиан Алексов
Игорь Локот
Original Assignee
Ардениа Инвестментс, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ардениа Инвестментс, Лтд. filed Critical Ардениа Инвестментс, Лтд.
Publication of EA201070625A1 publication Critical patent/EA201070625A1/ru
Publication of EA018636B1 publication Critical patent/EA018636B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В настоящем изобретении предложена система доставки лекарственного средства (СДЛ) для введения водорастворимого катионного и амфифильного фармацевтически активного вещества (ФАВ), при этом указанная СДЛ содержит плохо растворимые в воде наночастицы, образованные ФАВ совместно с натриевой солью метилового эфира N-полностью-транс-ретиноилцистеиновой кислоты и/или натриевой метилового эфира N-13-цис-ретиноилцистеиновой кислоты. Также предложена фармацевтическая композиция, содержащая указанную СДЛ, способы получения указанной СДЛ и указанной фармацевтической композиции, а также применение указанной СДЛ и фармацевтической композиции для лечения рака.
EA201070625A 2007-12-19 2008-12-18 Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества EA018636B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2007/001129 WO2009078756A1 (en) 2007-12-19 2007-12-19 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
PCT/SE2008/051516 WO2009078803A1 (en) 2007-12-19 2008-12-18 Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance

Publications (2)

Publication Number Publication Date
EA201070625A1 true EA201070625A1 (ru) 2010-12-30
EA018636B1 EA018636B1 (ru) 2013-09-30

Family

ID=40795734

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070625A EA018636B1 (ru) 2007-12-19 2008-12-18 Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества

Country Status (12)

Country Link
US (1) US8765173B2 (ru)
EP (1) EP2231192B1 (ru)
JP (1) JP5466173B2 (ru)
KR (1) KR101616134B1 (ru)
CN (1) CN101945670B (ru)
AU (1) AU2008339100B2 (ru)
BR (1) BRPI0821741B8 (ru)
CA (1) CA2709267C (ru)
EA (1) EA018636B1 (ru)
MX (1) MX2010006907A (ru)
NZ (1) NZ586853A (ru)
WO (2) WO2009078756A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009078754A1 (en) * 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
EP2425830A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synergistic drug combination for the treatment of cancer
CN102008444B (zh) * 2010-11-26 2012-06-20 北京工业大学 载有米托蒽醌的葡聚糖-聚乳酸共聚物纳米粒子的制备方法
EP3191138B1 (en) 2014-09-10 2024-05-29 Double Bond Pharmaceutical AB Targeted delivery of hydrophilic drugs
CN112321465B (zh) * 2019-07-18 2023-06-06 上海现代药物制剂工程研究中心有限公司 一种含苯基化合物、其中间体、制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
DE69932187T2 (de) * 1999-03-11 2007-05-24 Ardenia Investments Ltd. Verbindungen für krebs-therapie
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
SE0101702D0 (sv) * 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US20050249786A1 (en) 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
JP2004010479A (ja) * 2002-06-03 2004-01-15 Japan Science & Technology Corp ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法
SE0202311D0 (sv) * 2002-07-23 2002-07-23 Ardenia Investments Ltd Novel compounds, cytotoxic preparations comprising said compounds, methods of manufacture of said preparations, as well as methods of treatment
JP2006199590A (ja) * 2003-09-04 2006-08-03 Nano Career Kk 水溶性の塩基性薬物内包ナノ粒子含有組成物
US20050196343A1 (en) * 2004-02-27 2005-09-08 Molecular Therapeutics, Inc. Degradable nanoparticles
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
WO2007001356A2 (en) * 2004-09-10 2007-01-04 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
WO2009078754A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of poorly water soluble pharmaceutically active substances
WO2009078755A1 (en) 2007-12-19 2009-06-25 Ardenia Investments, Ltd. Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
US8197809B2 (en) 2008-06-25 2012-06-12 Korea Research Institute Of Bioscience And Biotechnology CD9-specific human antibodies

Also Published As

Publication number Publication date
WO2009078803A1 (en) 2009-06-25
WO2009078756A1 (en) 2009-06-25
CN101945670A (zh) 2011-01-12
MX2010006907A (es) 2010-11-10
JP2011507839A (ja) 2011-03-10
KR20100103588A (ko) 2010-09-27
CA2709267C (en) 2016-02-09
AU2008339100B2 (en) 2015-08-27
EA018636B1 (ru) 2013-09-30
BRPI0821741B8 (pt) 2021-05-25
CA2709267A1 (en) 2009-06-25
US20110123607A1 (en) 2011-05-26
US8765173B2 (en) 2014-07-01
BRPI0821741A2 (pt) 2015-06-16
JP5466173B2 (ja) 2014-04-09
EP2231192A4 (en) 2014-12-03
NZ586853A (en) 2012-06-29
CN101945670B (zh) 2012-08-22
KR101616134B1 (ko) 2016-04-27
EP2231192B1 (en) 2017-08-02
EP2231192A1 (en) 2010-09-29
BRPI0821741B1 (pt) 2020-11-17
AU2008339100A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
MY157187A (en) Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
BR112014010291A2 (pt) composições de lipossoma combinacionais para terapia de câncer
EA201070625A1 (ru) Система доставки лекарственного средства для введения водорастворимого катионного и амфифильного фармацевтически активного вещества
NO20075136L (no) Nye liposompreparater
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
RU2015103538A (ru) Способы лечения артрита
BRPI0507622A (pt) composto baseado em ácido hialurÈnico, sal de sódio, processo para preparar um composto ou um seu sal, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e, uso de composto ou de seu sal
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
AU2019268085A1 (en) Compound of glycosaminoglycan, preparation method and use thereof
EA201490653A1 (ru) Производные эстра-1,3,5(10),16-тетраен-3-карбоксамида, способ их получения, содержащие их фармацевтические препараты, а также их применение для получения лекарственных средств
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
BR112015010980A2 (pt) composição de excipientes e formas farmacêuticas de libertação prolongada com aumento de biodisponibilidade de drogas antibacterianas, drogas anticoccidianas e outros medicamentos para aves e suínos comerciais
EA201491427A1 (ru) Замещенные фенилимидазопиразолы и их применение
CY1121145T1 (el) Συστημα χορηγησης φαρμακων για χορηγηση μιας υδατοδιαλυτης, κατιοντικης και αμφιφιλης φαρμακευτικως ενεργης ουσιας
BR112014009242A2 (pt) nanossuspensão farmacêutica
CY1124893T1 (el) Φαρμακευτικο μeιγμα μαροπιταντης
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
UA109544C2 (uk) Фармацевтична композиція, що містить парацетамол, та спосіб її виготовлення

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment